Biotech · Private company · Framingham, MA, US
Alzheon, Inc.
SEC CIK 0001582636
Track this companyFree. Adds Alzheon, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials31 recruiting or active
Pipeline programs2From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline2
- Experimental: ALZ-801Phase 3 · Early Alzheimer's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- ALZ-507Phase 1 · Healthy Participants StudyClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- Safety and Pharmacokinetics of ALZ-507 in Healthy Elderly AdultsPHASE1 · RECRUITING · started Mar 9, 2026ClinicalTrials.gov NCT07824271 · fetched Nov 12, 2026
- Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD SubjectsPHASE3 · TERMINATED · started Apr 2, 2024ClinicalTrials.gov NCT06304883 · fetched Nov 12, 2026
- An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD SubjectsPHASE3 · COMPLETED · started May 19, 2021ClinicalTrials.gov NCT04770220 · fetched Nov 12, 2026
NIH awards1
- Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Fiscal year 2024 · $2.3MNIH RePORTER 5R01AG065253-05 · fetched Nov 12, 2026